Arkolith/Insider Trading/XERS/Form 4

Brady James Aloysius

DirectorXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Apr 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$60K
Net Open-Market Flow
-$60K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 30, 2026Sell(S)11K$5.54$60K89K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001916987-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML